Roche Ditches PhRMA for BIO

August 2009
Pharmaceutical Representative;Aug2009, Vol. 39 Issue 8, p9
The article reports on the confirmation of Hoffman-La Roche Ltd. concerning its withdrawal from being a member of the Pharmaceutical Research and Manufacturers Association (PhRMA) in the U.S. The company's decision to leave the association was driven by its purchase of Genentech Inc. which is a member of the Biotechnology Industry Organization (BIO). Moreover, Roche will not renew its membership with the Association of the British Pharmaceutical Industry (BPI).


Related Articles

  • Roche sets sight on Genentech.  // Pharmaceutical Technology Europe;Mar2009, Vol. 21 Issue 3, p10 

    The article reports on an offer of $86.50 per share made by Roche directly to the Genentech's shareholders. The offer replaces the public proposal issued by Roche in July 2008 to purchase all the publicly-held shares for $89 per share through a negotiated merger. Genentech seems unconvinced by...

  • Return Serve To Roche. P., Shankar // njbiz;8/18/2008, Vol. 21 Issue 34, p2 

    The article reports on the planned acquisition of drug company Roche to buy 44% of biotechnology company Genentech for $43.7 billion. The offer was rejected by Genentech and analysts believed Roche would improve its price. Roche is said to relocate its manufacturing functions to San Francisco,...

  • Roche, Genentech Finally Agree to Acquisition.  // Bioworld Week;3/16/2009, Vol. 17 Issue 11, p5 

    The article reports on the merging of Basel, Switzerland-based Roche Holdings AG and Genentech Inc. based in South Francisco, California. The merging was closed at the amount of about $46.8 billion. Under the deal, Roche will pay Genentech $95 per share for the remaining 44 percent of stocks...

  • Genentech Ramping Up North County Manufacturing. Chambers, Heather // San Diego Business Journal;8/3/2009, Vol. 30 Issue 31, p1 

    The article reports on the plan of Roche AG to acquire Genentech Inc. in a 47 billion dollars agreement to promote its position in cancer drugs in Oceanside, California in 2009. According to Genentech, approximately 500 workers responsible to produce batches of cancer drug Avastin will keep...

  • Pharma, Biotech Allies Replenish Pipeline. McGee, Patrick // Drug Discovery & Development;Aug2006, Vol. 9 Issue 8, p10 

    The article focuses on the significance of the merger between biotechnology company Genentech Inc. and Roche AG, a pharmaceutical firm, to the field of drug development in the U.S. The history of Genentech and how it was consolidated with Roche is discussed. Moreover, because of the risk of...

  • Roche now has partner for Ventana Medical. Smith, Nicholas // Inside Tucson Business;3/23/2009, Vol. 18 Issue 43, p1 

    The article reports on the acquisition of Genentech Inc. by pharmaceutical giant Roche Holding AG in Tucson, Arizona. It is noted that Roche paid $46.8 billion for the 44 percent of Genentech stock, which amounted the purchase price of $95 per share. Meanwhile, Roche has estimated that the...

  • Roche $43.7B Genentech Offer Likely to Feel Upward Pressure. Young, Donna // BioWorld International;7/23/2008, Vol. 13 Issue 30, p3 

    The article reports that Roche Holding AG has offered $43.7 billion to purchase the 44 percent it does not own already of Genentech Inc. If the merger is completed, Roche would gain worldwide control of Avastin, which Genentech markets in the U.S., and other cancer drugs like Herceptin and...

  • Goodbye Genentech, But No Obit for Biotech Yet, Please. Boggs, Jennifer // BioWorld Today;3/16/2009, Vol. 20 Issue 49, p1 

    The article focuses on the possible impact of the merger between Roche Holdings AG and Genentech Inc. on the biotechnology industry. In the said deal, Roche agreed to acquire the remaining shares of Genentech priced at $95 per share. Some speculate that the merger could have a large impact on...

  • Roche Goes Hostile, Takes Lower Offer to Genentech Shareholders. Boggs, Jennifer // BioWorld Today;2/2/2009, Vol. 20 Issue 20, p1 

    The article reports on the plans of Roche Holding AG to proceed under a hostile takeover, taking its revised offer to purchase the remaining 44 percent of Genentech Inc. for $86.50 per share. Genentech's committee chairman Charles A. Sanders has described Roche's move as an opportunistic step in...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics